◀ Back to AGTR1
AGTR1 — EGFR
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
Text-mined interactions from Literome
Fujiyama et al., Circ Res 2001
:
AT(2) inhibited
AT(1) mediated Ang2 expression and phosphorylation of
EGFR
Shibasaki et al., Hypertension 2001
:
AT(2) inhibited
AT(1) mediated
EGFR tyrosine phosphorylation by 63 %
Yin et al., Int J Biochem Cell Biol 2003
:
Besides coupling with heterotrimeric G proteins to activate phospholipase C-beta (PLC-beta),
AT1R also
activates receptor tyrosine kinases ( PDGF-R,
EGF-R and IGF-R ) and non-receptor tyrosine kinases ( Src, Fyn, Yes, proline-rich tyrosine kinase 2 (Pyk2), focal adhesion kinase ( FAK ) and JAK2 )
Eguchi et al., Biochem Soc Trans 2003
:
Here, we will discuss the
roles and mechanisms of
AngII/AT(1) receptor in promoting
ErbB receptors transactivation in VSMCs
Shah et al., Mol Endocrinol 2004
:
Although the Tyr319 residue of the AT1-R has been proposed to be an essential regulator of EGF-R transactivation, stimulation of wild-type and mutant ( Y319F )
AT1-R expressed in COS-7 cells
caused EGF-R transactivation and subsequent ERK1/2 phosphorylation through release of HB-EGF in a Src dependent manner
Olivares-Reyes et al., Mol Pharmacol 2005
:
Agonist activation of endogenous
AT(1)-Rs and EGF-Rs
induced the formation of a multireceptor complex containing both the AT(1)-R and the transactivated
EGF-R
Zhai et al., Circ Res 2006
(Cardiomegaly...) :
In conclusion, overexpression of
AT(1)-Y319F in cardiac myocytes
diminished EGFR transactivation and inhibited a pathological form of cardiac hypertrophy
Chan et al., J Recept Signal Transduct Res 2006
(Hypertrophy) :
These results challenge our perception of
AT1R mediated
EGFR transactivation and imply that truncated EGFRs may affect cell function through unconventional mechanisms
Li et al., Am J Physiol Heart Circ Physiol 2010
(Disease Models, Animal...) :
In addition, the enhanced phosphorylation of
EGF-R in VSMC from SHR compared with WKY was also
attenuated by inhibitors of
AT(1) , ET ( A ), ET ( B ), and EGF-R but not by inhibitors of platelet derived growth factor receptor or insulin-like growth factor receptor
Zou et al., J Cardiovasc Pharmacol 2012
(Cardiomegaly...) :
The possible mechanisms may involve inhibition of
angiotensin II type 1 receptor and
activation of
ErbB receptors